Company financially hurting

Quote
Agreed! With Brovana growth declining and having less then 2yrs left...and Lonhola killin’ It at $13m per yer...(prior to Yupelri kicking the shit out of it) were set up nicely to replace over a Billion dollar drug Seriously, I really hope all you Respiratory brothers and sisters are doing the right thing...
 






























Unbelievable push in respiratory at the end of Q1, but nary a word at the end Q2.

Cut budgets from basically unlimited to having only enough to do a couple good sized lunches and then buying several cases of Walmart water so we can hand out a bottle water at lunches, LTC, morning snack, afternoon snack and of course speaker programs. Good thing it’s summer - need these offices to stay hydrated.

Mileage logs - for real?

Meeting with no itinerary or instructions on making travel arrangements, hmm.
 






Do the math!
Roughly 160 reps with a couple layers of management, at a clip of around a couple hundred g’s per person. That’s not good business. Spending around $60MM and making around $15MM.
 






A year and a half in and the financial’s don’t look so good.
The only place really making money is in LTC. Uhm, working on LTC modules for the “upcoming” meeting, while management is expanding a double secret sales force into LTC as we speak.
 


















Let's see...........
200 million upfront for BBI, plus unknown amount in developmental costs
450 million for the ciclesonide molecule rights
624 million yo buy Cynapsus--the company with apomorphine
75 million dollars for the rights to eslicarbazepine from Bial
Millions for Utibron, Arcapta, and Seebri
Up to 430 million for Lonhala when it bought Elevation Pharma (100 mil upfront
100 mil on approval, and later payments)

I would like to ask all of you still holding on at this company: Do you think this was money well spent?
 












Lol. The respiratory franchise is a lead anchor. Ride Latuda and Brovana revenues as long as they last. It doesn't take a rocket scientist to recognize that major changes/downsizing is necessary. It has to happen soon.
 






The smart people have already left. Most of the top performers who remain are interviewing and trying to leave. We are not backfilling positions.... key corporate level executive positions have been vacant for a long period of time.... THAT SPELLS TROUBLE !!
 


















anonymous said:
The smart people have already left. Most of the top performers who remain are interviewing and trying to leave. We are not backfilling positions.... key corporate level executive positions have been vacant for a long period of time.... THAT SPELLS TROUBLE !!
Click to expand...

If we hit their magic number by the end of FY2019, do you think the hiring freeze will be lifted for Respi? I can’t decide if I think they are giving us more time or if they are only postponing a decision that has already been made to see how this HUB stuff plays out as a trial run for the neurology drug before launch.
 






I believe the latter. I think decision is already made. Even if they hit 38 million, that still does not cover respiratory payroll..... let alone other sales and marketing expenses.
 


















Top Bottom
Back
Quote